Now available: Small, cost-effective liquid biopsy NGS assay
AmoyDx® HRR Liquid NGS Panel: Detection of mutations in 24 genes
The AmoyDx® HRR Liquid NGS Panel (RUO) is an NGS assay for the qualitative detection of mutations (SNVs, InDels) in 20 HRR genes as well as PTEN, AKT1, PIK3CA and AR on cfDNA from blood plasma. The small, cost-effective panel covers the most important HRR genes including all genes mentioned in the S3 guideline “Prostate cancer”, version 7.0, May 2024 in the context of a PARPi therapy [1].
The library is prepared using the hybrid capture method (ddCAP technology) over two days and the sequence data is analyzed locally by the AmoyDx® NGS Data Analysis System (ANDAS).
For more information, please click here.
Alternatively, you can contact us directly at molpath@zytomed-systems.de
Stay tuned for more liquid biopsy products coming soon.
[1] S3-Leitlinie Prostatakarzinom Version 7.0 – Mai 2024 AWMF-Registernummer: 043-022OL
Further topics
Qualitative detection of NTRK3 and NTRK1 break apart
Recently, a second ZytoDot ® 2C probe for detecting rearrangements of the NTRK genes has become available: the new ZytoDot ® 2C SPEC NTRK3 Break Apart Probe (C-3079-100). Together with the already existing ZytoDot ® 2C SPEC NTRK1 Break Apart Probe (C-3078-100), a large range of NTRK rearrangements can be covered now. Both probes are designed for the qualitative detection of NTRK3 and NTRK1 rearrangements in FFPE tissue using the ZytoDot ® 2C CISH implementation Kit.
Breast Cancer Awareness Month
Breast cancer is one of the most common cancers in women worldwide. In Germany, every 8th woman is diagnosed with breast cancer. Until now, therapies have been based on the presence/absence of (hormone) receptors or the Her2 receptor in metastatic/non-metastatic breast cancer.
